Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Nitric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1184608 | 0.88 | PLAU (0.54) | PLAUPLGKMT2AMEN1MAPT | |
| Nitric Acid SCHEMBL4476359 | 0.86 | TMPRSS4 (0.46) | PLAUPLGKMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL25329480 | 0.86 | PLAU (0.53) | PLAUPLGKMT2AMEN1MAPT | |
| Nitric Acid SCHEMBL1363033 | 0.85 | PLAU (0.54) | PLAUKMT2AMEN1MAPTMAPK1 | |
| Nitric Acid SCHEMBL5354098 | 0.84 | ALDH1A1 (0.52) | KMT2AMEN1MAPTHTTSMN1; SMN2 | |
| Nitric Acid SCHEMBL4162364 | 0.81 | L3MBTL1 (0.46) | KMT2AMEN1MAPTMAPK1POLB | |
| Nitric Acid SCHEMBL20984900 | 0.80 | KMT2A (0.46) | PLAUKMT2AMEN1MAPTMAPK1 | |
| Nitric Acid SCHEMBL1185356 | 0.78 | ALOX5 (0.56) | KMT2AMEN1MAPTMAPK1HTT | |
| Nitric Acid SCHEMBL6034752 | 0.78 | ALOX5 (0.56) | KMT2AMEN1MAPTMAPK1HTT | |
| Nitric Acid SCHEMBL1184113 | 0.78 | CYP1A2 (0.44) | KMT2AMEN1MAPTHTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799684-B1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARM INC (US) | 2014-12-03 | — | — | EP | disclosed |
| CN-102766142-A | Lactam compounds useful as protein kinase inhibitors | MILLENIUM PHARMACEUTICALS INC | 2012-11-07 | — | — | CN | disclosed |
| CN-101068815-B | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-07-12 | — | — | US | disclosed |
| US-7935694-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-7582630-B2 | Pyradazine compounds as GSK-3 inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-01 | — | — | US | disclosed |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-7459448-B2 | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| CN-101068815-A | Lactam compounds useful as protein kinase inhibitors | MILLENNIUM PHARM INC (US) | 2007-11-07 | — | — | CN | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-6552029-B1 | For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis | CELLTECH R&D LIMITED (GB) | 2003-04-22 | — | — | US | disclosed |
| EP-0934304-B1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| CN-1370152-A | 5-cyano-2-aminopyrimidine derivatives | CELLETECH CHIROSCIENCE LTD (GB) | 2002-09-18 | — | — | CN | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| US-6114333-A | 2-Pyrimidineamine derivatives and processes for their preparation | CELLTECH THERAPEUTICS LTD. (GB) | 2000-09-05 | — | — | US | disclosed |
| EP-0934304-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998018782-A1 | 2-PYRIMIDINEAMINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | CELLTECH THERAPEUTICS LIMITED (GB) | 1998-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178739-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | PLAU 2556/4885PLG 3244/4885KMT2A 2007/4885 |
| US-20090105213-A1 | Lactam compounds useful as protein kinase inhibitors | PRKCI, PIK3CA, AKT1 | PLAU 2556/4885PLG 3244/4885KMT2A 2007/4885 |
| US-20110039820-A1 | LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | PRKCI, PIK3CA, AKT1 | PLAU 2556/4885PLG 3244/4885KMT2A 2007/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | PLAU 3100/4885PLG 2134/4885KMT2A 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.